

Client: Primal King Peptides

Certified: 09/02/2026

This Certificate of Analysis certifies that the sample listed herein was tested by Kovera Labs using validated analytical methods and was found to meet the stated specifications at the time of analysis.

SAMPLE INFORMATION

Product	CJC-1295 (No DAC)/Ipamorelin	Form	Lyophilized Powder
Batch	N/A	Labeled Qty	10 mg
Cap Color	White	Crimp Color	Silver

TEST RESULTS

	REFERENCE STANDARD	RESULT
Blend Avg Purity	(>98%)	99.406%
Blend Avg Net Content	(~10mg)	11.61 mg
Blend Identification (LC-MS)	(CJC-1295 (No DAC)/Ipamorelin)	CJC-1295 (No DAC)/Ipamorelin
Endotoxin Safety Screen	(≤0.5 EU/mL)	PASS
Fentanyl Presence Analysis	(Not Detected)	Not Detected
14 Day Sterility Screening	(No Growth)	No Growth

BLEND COMPONENT ANALYSIS



Component	Labeled	Measured
Ipamorelin	5 mg	5.68 mg
CJC-1295 (No DAC)	5 mg	5.93 mg

HEAVY METAL SCREENING

Analyte	Result	Status
Arsenic (As)	Negative	
Cadmium (Cd)	Negative	
Lead (Pb)	Negative	
Mercury (Hg)	Negative	

CHROMATOGRAM

Method: RP-HPLC | Column: C18 | Detection: DAD @ 214 nm



CLIENT & SAMPLE INFORMATION

Client	Primal King Peptides	Certified Date	09/02/2026
Product Name	CJC-1295 (No DAC)/Ipamorelin	Strength	10 mg
Lot / Batch	N/A	Condition	Lyophilized

This Certificate of Analysis certifies that the sample listed herein was tested for bacterial endotoxin using a kinetic chromogenic LAL assay in accordance with USP <85> Bacterial Endotoxins Test.

TEST METHODOLOGY

Test Performed	Quantitative Bacterial Endotoxin Test	Compendial Ref	USP <85>
Assay Type	Kinetic Turbidimetric	Detection λ	660 nm
Detection Range	0.01 - 1.0 EU/mL	Endotoxin Std	E. coli O111:B4
Dilution Vol	2.0 mL	Matrix	LAL Reagent Water

QUANTITATIVE RESULTS

Parameter	Result
Endotoxin Level	< 0.06 EU/mL
Acceptance Limit	≤ 0.5 EU/mL
Sample CV (%)	3.5%
Spike CV (%)	5.0%
Spike Recovery (%)	84%
Final Determination	PASS

CONTROLS

Control	Expected	Observed	Status
Positive Control	Detectable	As expected	Pass
Negative Control	No signal	As expected	Pass

INTERPRETATION

Endotoxin content was quantitatively determined using a kinetic chromogenic LAL assay in accordance with USP <85>. Result reported as below quantitation threshold. The measured endotoxin level meets the specified acceptance criteria. The sample passes the endotoxin limit test.

AUTHORIZATION

REVIEWED BY
Lemar Arghandiwal
Lab Director



CLIENT & SAMPLE INFORMATION

Client	Primal King Peptides	Certified Date	August 11, 2026
Product Name	CJC-1295 (No DAC)/Ipamorelin	Strength	10 mg
Lot / Batch	N/A	Condition	Lyophilized

ICP-MS metals analysis performed using EPA-referenced methods; results evaluated against internal acceptance criteria.

TEST METHODOLOGY

Test Performed	Elemental Impurities Analysis	Instrument	ICP-MS
Sample Prep	HNO ₃ / H ₂ O ₂ matrix	Calibration	Multi-element standard curve
Internal Std	Sc, Ge, In, Bi	Material Type	Raw Material (Research Use)

ELEMENTAL IMPURITIES RESULTS

Element	Result (ppm)	Acceptance Limit (ppm)	Status
Pb Lead	< 0.5	≤ 10	PASS
As Arsenic	< 0.15	≤ 1.5	PASS
Cd Cadmium	< 0.05	≤ 0.5	PASS
Hg Mercury	< 0.3	≤ 3	PASS

METHOD SUITABILITY (SPIKE RECOVERY)

Element	Spike Level	Recovery	Criteria
Pb Lead	5 ppm	98%	70–150%
As Arsenic	0.75 ppm	102%	70–150%
Cd Cadmium	0.25 ppm	95%	70–150%
Hg Mercury	1.5 ppm	91%	70–150%

Spike recovery confirms method suitability for the sample matrix.

INTERPRETATION

Elemental impurities were determined using ICP-MS with EPA-referenced analytical methods. All tested elements (Pb, As, Cd, Hg) are below the stated acceptance limits. Spike recovery values fall within acceptable ranges, confirming method suitability. The sample meets the stated acceptance criteria for elemental impurities.

QUALITY CONTROL

Method Blank: Pass CCV: Pass Duplicate RPD: < 20%

AUTHORIZATION

REVIEWED BY
Lemar Arghandiwal
Lab Director





CLIENT & SAMPLE INFORMATION

Client	Primal King Peptides	Certified Date	09/16/2026
Product Name	CJC-1295 (No DAC)/Ipamorelin	Strength	10mg
Lot / Batch	N/A	Condition as Received	Sealed injectable vial

This report summarizes microbial growth screening performed on the submitted sample using the BacT ALERT automated microbial detection system. The test is designed to screen for detectable microbial growth under the conditions of the method used. This report applies only to the submitted sample as tested and does not certify sterility of the entire batch lot or product line.

TEST METHODOLOGY

Test Performed	14 Day Microbial Growth Screening
Culture System	Aerobic and anaerobic culture bottles
Incubation Period	14 days
Detection Principle	Colorimetric CO ₂ detection
Sample Requirement	1 vial (destructive)

TEST RESULTS

Parameter	Result
Aerobic microbial growth	No Growth
Anaerobic microbial growth	No growth detected
Final Determination	No microbial growth detected during the 14 day incubation period

METHOD OVERVIEW

The submitted sample was aseptically introduced into BacT ALERT culture bottles designed to support microbial growth detection. The BacT ALERT system continuously monitors each bottle during incubation. If microorganisms are present and grow, they may produce carbon dioxide (CO₂) which interacts with the colorimetric sensor in the bottle; the instrument detects this change photometrically. If growth is detected, the system automatically flags the bottle as positive and records the time to detection. If no growth is detected during the full incubation period, the final result is reported as no microbial growth detected.

INTERPRETATION

No microbial growth was detected in the submitted sample during the 14 day BacT ALERT incubation period. This result indicates that no detectable microbial growth was observed under the conditions of this screening method. This result should not be interpreted as a guarantee of sterility for the entire batch lot or product line.




Mass Spectrometry Report

LC/MS (ESI Q-TOF) identity confirmation

CJC-1295 (NO DAC)/IPAMORELIN - DETECTED

Sample Name : PRI-149599 EB977E CJC12/IPA 10mg Blend : CJC-1295 (No DAC)/Ipamorelin
Report ID : KVR-2026-EB977E Order : PRI-149599
Acquired : 2026-09-07 00:52:53 Polarity : + (ESI)
Components : 2/2 confirmed Coverage : 6/8 (75%)



Blend Components - Targeted Identity per Component

Component	Label	Expected mass	States	Coverage	Scan RT	Verdict
Ipamorelin	5 mg	711.39 Da	1/1	100%	3.61	CONFIRMED
CJC-1295 (No DAC)	5 mg	3365.89 Da	5/7	71%	5.20	CONFIRMED

Observed neutral mass (deconvoluted): 3367.91 Da [5 charge states, high confidence] - a blend spectrum contains every component, so a single deconvoluted mass describes only the dominant species

Note: all 2 blend components confirmed (Ipamorelin, CJC-1295 (No DAC)); 6/8 charge states across the blend [Ipamorelin] confirmed: 1/1 charge states (coverage 100%), expected 711.39 Da (monoisotopic) @ RT 3.61 min [CJC-1295 (No DAC)] confirmed: 5/7 charge states (coverage 71%), expected 3365.89 Da (monoisotopic) @ RT 5.20 min


Mass Spectrometry Report

LC/MS (ESI Q-TOF) identity confirmation


IPAMORELIN - DETECTED

Sample Name : PRI-149599 EB977E CJC12/IPA 10mg Compound : Ipamorelin
Report ID : KVR-2026-EB977E Order : PRI-149599
Acquired : 2026-09-07 00:52:53 Polarity : + (ESI)
Expected : 711.39 Da (monoisotopic) Coverage : 1/1 (100%)

BLEND COMPONENT: Ipamorelin (5 mg label claim)



MS Spectrum at 3.61 min - target envelope apex




Mass Spectrometry Report

LC/MS (ESI Q-TOF) identity confirmation


CJC-1295 (NO DAC) - DETECTED

Sample Name : PRI-149599 EB977E CJC12/IPA 10mg Compound : CJC-1295 (No DAC)
Report ID : KVR-2026-EB977E Order : PRI-149599
Acquired : 2026-09-07 00:52:53 Polarity : + (ESI)
Expected : 3365.89 Da (monoisotopic) Coverage : 5/7 (71%)

BLEND COMPONENT: CJC-1295 (No DAC) (5 mg label claim)



MS Spectrum at 5.20 min - target envelope apex



Adulterant & Excipient Screen

Presumptive accurate-mass screen of EVERY MS1 scan for common RUO excipients/fillers and controlled-substance adulterants (fentanyl class), matched through $[M+H]^+$, $[M+Na]^+$, $[M+K]^+$, $[M+NH_4]^+$ adducts.

FENTANYL / ADULTERANT SCREEN: NOT DETECTED

No library excipients or adulterants detected above the screen threshold.


SCREEN, NOT CONFIRMATION. Single-stage accurate-mass ESI+ cannot distinguish isobaric compounds without MS/MS. A hit is a presumptive flag; confirm any controlled-substance (fentanyl-class) detection by MS/MS or a reference standard before any release or reporting decision. Absence of a hit does not guarantee absence of an adulterant outside this library or below the screen threshold. Excipient/filler hits are expected in many RUO products (lyoprotectants, buffers, bacteriostatic agents) and are informational.

Mass Spectrometry Report

LC/MS (ESI Q-TOF) identity confirmation

UV / DAD Chromatogram

Diode-array trace acquired on the same injection as the MS data. Channel: 214 nm



NO UV BAND CORRESPONDS TO THE ORDERED COMPOUND'S MS ION. The marked peak (3.42 min) is a different chromatographic feature and must not be read as the ordered compound. DETECTOR OVERLOAD: this trace exceeds the ~1500 mAU linear range of the detector, so the peak top is clipped and may split into two apexes. No net content or purity is derived from this trace on this report - the DAD trace is used here for identification support only.